| Q58699463 | A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B |
| Q64055745 | A case-control study of risk factors for hepatitis B infection: A regional report among Isfahanian adults |
| Q38211373 | A drug safety evaluation of rituximab and risk of hepatitis B. |
| Q45412287 | A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues |
| Q33368982 | A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. |
| Q46732231 | A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial |
| Q90198704 | APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation |
| Q27022622 | Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B |
| Q56430379 | Acute liver failure |
| Q91911417 | Akutes Leberversagen |
| Q90127495 | Analysis of Hepatitis B Virus Reactivation After Radiotherapy in Patients With Hepatocellular Carcinoma Using the Lyman NTCP Model |
| Q37001173 | Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy |
| Q26801716 | Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) |
| Q33374113 | Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation |
| Q45324587 | Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy |
| Q45388537 | Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience |
| Q34404991 | Chemotherapy-related reactivation of hepatitis B infection: updates in 2013. |
| Q37566301 | Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review |
| Q27006996 | Clinical impact of occult hepatitis B virus infection in immunosuppressed patients |
| Q36364001 | Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy |
| Q40642803 | Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy |
| Q40152808 | Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. |
| Q30248818 | Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis |
| Q52604921 | Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. |
| Q40870495 | Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis |
| Q34974883 | Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists |
| Q91655795 | Defining and grading HBV reactivation |
| Q36379054 | Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy |
| Q59349442 | Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation |
| Q54984291 | Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study. |
| Q37524976 | Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. |
| Q38134026 | Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. |
| Q45422025 | Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment |
| Q40405411 | Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations |
| Q36704509 | Fulminant hepatitis following chemotherapy treatment for breast cancer |
| Q37305399 | Gastrointestinal complications of oncologic therapy |
| Q83078603 | HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting |
| Q41197534 | HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease |
| Q40633899 | HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea |
| Q90193374 | Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management |
| Q41111818 | Hepatic encephalopathy associated with cancer or anticancer therapy. |
| Q38755178 | Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions |
| Q28076703 | Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened |
| Q59349834 | Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma |
| Q38643394 | Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. |
| Q36958944 | Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy |
| Q91706568 | Hepatitis B Virus Reactivation in the Setting of Immunosuppressive Drug Therapy |
| Q89474283 | Hepatitis B Virus Reactivation under Treatment with Nilotinib |
| Q90611480 | Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies |
| Q35771194 | Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. |
| Q39683646 | Hepatitis B and C prophylaxis in patients receiving chemotherapy |
| Q26781993 | Hepatitis B and Hepatitis C Reactivation in the Biologic Era |
| Q26776468 | Hepatitis B and cancer: A practical guide for the oncologist |
| Q41690596 | Hepatitis B in patients with hematological diseases: An update |
| Q35597892 | Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy |
| Q47178355 | Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. |
| Q37205405 | Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience |
| Q36654518 | Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor |
| Q37764963 | Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management |
| Q39293427 | Hepatitis B reactivation in patients receiving targeted therapies |
| Q35567748 | Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure |
| Q91916229 | Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand |
| Q40208015 | Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. |
| Q33825391 | Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis |
| Q42163204 | Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy |
| Q45364479 | Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. |
| Q38155954 | Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs |
| Q36245362 | Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management |
| Q45268408 | Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management |
| Q36581066 | Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis |
| Q42201621 | Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant |
| Q36896193 | Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours |
| Q26785963 | Hepatitis B virus reactivation with a rituximab-containing regimen |
| Q26830484 | Hepatitis B virus reactivation with rituximab-containing regimen |
| Q36368747 | Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area |
| Q35606765 | High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia |
| Q41107043 | How I treat acute myeloid leukemia presenting with preexisting comorbidities |
| Q92874253 | Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression |
| Q42764680 | Immunosuppression in Patients with Chronic Hepatitis B. |
| Q59360966 | Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report |
| Q38335718 | Infection risk associated with anti-TNF-α agents: a review |
| Q41700506 | Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series |
| Q42244740 | JSH Guidelines for the Management of Hepatitis B Virus Infection |
| Q36153966 | KASL Clinical Practice Guidelines: Management of chronic hepatitis B. |
| Q26752475 | KASL clinical practice guidelines: management of chronic hepatitis B |
| Q44242208 | Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy |
| Q45419941 | Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma |
| Q37647468 | Late Reactivation of Hepatitis B Virus after Chemotherapies for Hematological Malignancies: A Case Report and Review of the Literature |
| Q37067589 | Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. |
| Q38071405 | Management of HBV in immunocompromised patients |
| Q36220459 | Management of hepatitis B reactivation in patients receiving cancer chemotherapy. |
| Q42240045 | Management of hepatitis B virus-related acute liver failure |
| Q26853490 | Management of patients with hepatitis B who require immunosuppressive therapy |
| Q45355599 | Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic |
| Q91655790 | Medical interventions associated with HBV reactivation: Common and less common |
| Q55479805 | Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma. |
| Q34441838 | North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme |
| Q40285910 | Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis |
| Q91876310 | Optimal timing of antiviral therapy for patients with malignant tumor who presented with hepatitis B reactivation during chemotherapy and/or immunosuppressive therapy |
| Q36510947 | Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy |
| Q35429416 | Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening |
| Q35875680 | Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors. |
| Q38688782 | Prevention and management of hepatitis B virus reactivation in cancer patients |
| Q28070090 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy |
| Q40830395 | Prevention of HBV reactivation in patients treated with biologic agents. |
| Q26747023 | Prevention of Hepatitis B reactivation in the setting of immunosuppression |
| Q45356997 | Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy |
| Q33390799 | Prevention of hepatitis B virus reactivation under rituximab therapy |
| Q38202583 | Prevention of infection in cancer patients |
| Q45351504 | Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis |
| Q36957087 | Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis |
| Q35375654 | Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients |
| Q34627978 | Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy |
| Q42224704 | Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy |
| Q45369749 | Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts |
| Q92418314 | Reactivation of Hepatitis B Virus Infection With Reverse Seroconversion Following Umbilical Cord Allogeneic Hematopoietic Cell Transplantation in a Hepatitis-B-Immune Patient: A Case Report |
| Q37978202 | Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer |
| Q37798175 | Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy |
| Q37526652 | Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma |
| Q38062818 | Reactivation of hepatitis B virus in patients receiving chemotherapy |
| Q45413107 | Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents |
| Q36150595 | Reactivation of hepatitis B virus with rituximab. |
| Q37462566 | Reactivation of hepatitis B. |
| Q27028034 | Recent advances in management of acute liver failure |
| Q57809331 | Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy |
| Q35746079 | Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis |
| Q41215683 | Rituximab administration and reactivation of HBV. |
| Q36871718 | Rituximab-related viral infections in lymphoma patients |
| Q35045736 | S-phase arrest after vincristine treatment may promote hepatitis B virus replication |
| Q36752181 | Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies |
| Q39253757 | Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell Transplant |
| Q36597776 | Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection |
| Q64241456 | Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL |
| Q36616847 | Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study |
| Q36154994 | The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy |
| Q37800677 | The Gastrointestinal Complications of Oncologic Therapy |
| Q35057889 | The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system |
| Q40727234 | The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours |
| Q37886158 | Treatment of special populations with chronic hepatitis B infection |
| Q50190669 | Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance |
| Q35584210 | When treating cancer, please don't forget hepatitis B. |
| Q81710244 | [Chronic hepatitis B: unusual situations: dialysis, renal transplantation and pre-emptive therapy in immune compromised patients] |